Skip to main content

Table 1 Ongoing clinical trials studying anti-IL-1 strategies (except IL-1β strategies for lung cancer, shown in Table 2), alone or in combination, for cancer treatment

From: Targeting interleukin-1β and inflammation in lung cancer

Therapy Target Tumor type Recruitment status Study type ClinicalTrials.gov identifier Trial name Start date Estimated completion date
Anakinra + chemotherapy IL-1R Pancreatic adeno-carcinoma Active, not recruiting Phase I NCT02550327 [30] January 16 August 2023
Anakinra + denosumab + everolimus IL-1R, RANKL, and mTOR Advanced, metastatic, recurrent or refractory cancer Active, not recruiting Phase I NCT01624766 [31] June 2012 June 2020
CAN04 + chemotherapy IL-1RAP NSCLC, pancreatic ductal adenocarcinoma, TNBC, CRC Recruiting Phase I/II NCT03267316 [32] CANFOUR December 2017 June 2021
CAN04 + pembrolizumab IL-1RAP, PD-1 NSCLC, urothelial carcinoma, malignant melanoma, HNSCC Recruiting Phase I NCT04452214 [33] September 2020 January 2022
Canakinumab IL-1β Chronic myelomonocytic leukemia or myelodysplastic syndrome Recruiting Phase II NCT04239157 [34] August 2020 December 2022
Canakinumab + spartalizumab IL-1β, PD-1 Melanoma Recruiting Phase II NCT03484923 [35] PLATforM September 2018 April 2022
Canakinumab + spartalizumab + LAG525 IL-1β, PD-1, LAG-3 TNBC Recruiting Phase Ib NCT03742349 [36] January 2019 January 2022
Canakinumab + spartalizumab + chemotherapy IL-1β, PD-1 Pancreatic ductal adenocarcinoma Recruiting Phase Ib NCT04581343 [37] PanCAN-SR1 October 2020 March 2022
Canakinumab + spartalizumab IL-1β, PD-1 RCC Recruiting Phase I NCT04028245 [38] SPARC-1 August 2019 December 2021
Gevokizumab + bevacizumab/ramucirumab/cabozantinib + chemotherapy IL-1β, VEGF, VEGFR2 CRC, gastroesophageal cancer, RCC Recruiting Phase I NCT03798626 [39] May 2019 Jul 2024
  1. Abbreviations: CRC colorectal cancer, HNSCC head and neck squamous cell carcinoma, IL-1β interleukin-1β, IL-1R interleukin-1 receptor, IL-1RAP interleukin-1 receptor accessory protein, LAG-3 lymphocyte-activation gene 3, NSCLC non-small cell lung cancer, PD-1 programmed death-1, RANKL receptor activator of nuclear factor kappa-Β ligand, RCC renal cell carcinoma, TNBC triple negative breast cancer, VEGF vascular endothelial growth factor, VEGFR2 vascular endothelial growth factor receptor 2